(2025) T2DM: 46.5% discontinued by 1 year 64.1% discontinued by 2 years Without T2DM: 64.8% discontinued by 1 year 84.4% discontinued by 2 years Key Factors Linked to Discontinuation: Higher rates among patients without T2DM Age 65 years More likely to discontinue Higher weight loss during treatment Associated with lower discontinuation rates Moderate to severe GI side effects Higher likelihood of stopping treatment Higher income (T2DM only) Lower discontinuation rates Reinitiation of GLP-1: Source: Rodriguez PJ, Zhang V, Gratzl S, et al
Vertical integration In recent years, CVS, UnitedHealth, and Cigna have come under fire over accusations that their pharmacy benefit managers (PBMs) have monopolized the healthcare industry
2 1-2 - 2 , 1-2 - 270 135 47% You've reached the max limit for this item
[Google Scholar] 35.Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., Ciani S., Messeri G., Rotella C.M
Do endocrinologists treat thyroid-related weight gain
2 4 CDMO/CMO Partnerships Big Pharma Demos Find out how GLP-1 Technology can aid you in solving your issue No Peptide Team to access the market
